- Companies
- nference
nference Funding, Investors & Competitors
nference has raised $153M across 5 funding rounds, most recently a $3M seed round in November 2022.
Last nference funding round
$3M
Seed · Nov 2022
Cumulative funding nference raised
$153M
across 5 funding rounds
Key investors in nference
Matrix Partners
Matrix Capital Management
Mayo Clinic Ventures
NTT Venture Capital
A&E Investments
About nference
nference is a Cambridge, Massachusetts-based company, founded in 2013, that uses AI and neural networks in its nferX platform to synthesize unstructured biomedical data, including clinical notes, scientific literature, pathology images, ECG waveforms, and genomic sequences, into insights for drug discovery, clinical research, and trial operations. The company collaborates with biopharmaceutical companies, academic medical centers, and health systems, including Mayo Clinic, to advance diagnostics and therapeutics.
Founded
2013
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
nference Funding History
nference has raised a total of $153M across 5 funding rounds.
nference's first fundraising round was a $3M seed round in January 2016. The most recent completed round was a $3M seed round in November 2022.
nference funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Nov 2022 | Seed | - | $3M | nference is an AI-powered software platform that synthesizes unstructured biomedical data, including clinical notes, scientific literature, pathology images, ECG waveforms, and genomic sequences, into actionable insights for drug discovery, clinical research, trial operations, and lifecycle management in life sciences. The company uses neural networks in its nferX augmented intelligence platform to make siloed biomedical knowledge computable across healthcare enterprises. Founded in 2013 and headquartered in Cambridge, MA, nference collaborates with biopharmaceutical companies, academic medical centers, and health systems like Mayo Clinic to advance diagnostics and therapies. nference raised a $60 million Series B round announced January 8, 2020, led by Matrix Partners with participation from Matrix Capital Management, Mayo Clinic Ventures, and NTT Venture Capital. A $60 million Series C round followed, led by Matrix Capital Management with the same co-investors, bringing total funding over $130 million by early 2020 to expand its platform and portfolio. An unattributed round of $2.74 million occurred on November 4, 2022, with undisclosed investors, contributing to total funding of approximately $146 million across multiple rounds. |
| Dec 2020 | Series C | Matrix Partners (lead); Matrix Capital Management (lead); Mayo Clinic Ventures (lead); NTT Venture Capital (lead); A&E Investments | $66M | nference is an AI-driven health technology company headquartered in Cambridge, Massachusetts that synthesizes biomedical knowledge through its nferX software platform. The platform combines scientific literature, clinical and regulatory filings with genomics data and molecular data to provide biomedical data analytics for the life sciences sector. nference formed an exclusive collaboration agreement with Mayo Clinic in January 2020 to deidentify and synthesize data including electronic health records, laboratory reports, pathology images and physician notes. In December 2020, nference completed a $60 million Series C funding round led by Matrix Capital Management, with participation from Matrix Partners, Mayo Clinic Ventures and NTTVC. The funding was intended to support software development, learning models, and expansion of the company's portfolio to accelerate development of novel diagnostics and therapeutics. At the time of the Series C, nference was engaged in projects including understanding critical characteristics of SARS-CoV-2 virus transmission, symptoms and progression of COVID-19, and diagnostic predictions of chronic conditions such as pulmonary hypertension. The company had previously raised $60 million in a Series B round in January 2020, also from the same core investor group, and $11 million in Series A funding in mid-2018. |
| Jan 2020 | Series B | Matrix Partners (lead); Matrix Capital Management (lead); Mayo Clinic Ventures (lead); NTT Venture Capital (lead) | $69M | nference is an augmented intelligence software company headquartered in Cambridge, Massachusetts that synthesizes biomedical knowledge into actionable insights through its nferX platform. The company applies state-of-the-art neural networks to extract intelligence from scientific, clinical, regulatory, and commercial datasets, supporting applications across the life sciences ecosystem. Founded by Murali Aravamudan and Venky Soundararajan, the company is led by a multidisciplinary team including entrepreneurs and PhDs from MIT and Harvard Medical School. In January 2020, nference completed a Series B funding round of $69 million. In December 2020, the company announced completion of a $60 million Series C funding round led by Matrix Capital Management, with participation from Matrix Partners, Mayo Clinic Ventures, and NTTVC. The Series C funding supported software development and machine learning models, with projects including analysis of SARS-CoV-2 virus characteristics, COVID-19 symptom progression, and diagnostic predictions for chronic conditions such as pulmonary hypertension. Cumulative funding through November 2022 reached $146.34 million across multiple rounds. |
| Jun 2018 | Series A | Matrix Partners (lead); Matrix Capital Management (lead) | $12M | nference raised $11 million in a Series A funding round on approximately June 6, 2018, led by Matrix Partners with participation from existing investor Matrix Capital Management. The Cambridge, MA-based company develops an AI platform to synthesize biomedical knowledge from unstructured, semi-structured, and structured data sources such as clinical notes, scientific literature, pathology images, ECG waveforms, and genomic sequences. Funds were allocated to advance the company's AI and R&D platforms, expand scientific operations in Cambridge, and establish nference Labs in Bangalore, India. |
| Jan 2016 | Seed | Matrix Capital Management; Matrix Partners | $3M | - |
Who has invested in nference?
5 investors have backed nference across its funding rounds, including Matrix Partners, Matrix Capital Management, Mayo Clinic Ventures, NTT Venture Capital and A&E Investments.
Lead investors include Matrix Partners, Matrix Capital Management, Mayo Clinic Ventures and NTT Venture Capital.
nference Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Jan 2016 | ||
| 4 | Lead | Jan 2016 | ||
| 2 | Lead | Jan 2020 | ||
This data is available for Pro users. Sign up to see all 5 nference investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by nference
nference has acquired 1 company to date.
Last acquisition by nference was on May 11th 2022. nference acquired Predible Health for undisclosed valuation.
Latest Acquisitions by nference
| Description | Predible Health is an artificial intelligence platform in radiology tailored for specialists. LungIQ is designed from the ground up using deep learning technology trained on millions of CT images to deliver accurate and quantitative reports for referring pulmonologists. |
| HQ Country | |
| HQ City | Bangalore |
| Deal Date | 11 May 2022 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all nference acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by nference
nference has invested in 1 company to date.
Latest investment by nference was on May 1st 2021. nference invested in Anumana in their $60M Series B round.
Latest Investments by nference
| Description | Anumana is a New York-headquartered developer of AI algorithms analyzing electrocardiogram data for early detection of cardiovascular diseases like atrial fibrillation. The company collaborates with Mayo Clinic and holds FDA clearances for its diagnostic tools. Anumana extends its platform to perioperative and acute care settings to support clinicians across the cardiac care continuum. | Anumana is a New York-headquartered developer of AI algorithms analyzing electrocardiogram data for early detection of cardiovascular diseases like atrial fibrillation. The company collaborates with Mayo Clinic and holds FDA clearances for its diagnostic tools. Anumana extends its platform to perioperative and acute care settings to support clinicians across the cardiac care continuum. |
| HQ Country | ||
| HQ City | - | - |
| Deal Date | 1 May 2021 | 14 Apr 2021 |
| Round | Series B | Series A |
| Raised | $60M | $26M |
| Investors | NTT Venture Capital; Mayo Clinic Ventures; Matrix Capital Management; Matrix Partners | NTT Venture Capital; Mayo Clinic Ventures; Matrix Capital Management; Matrix Partners |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all nference investments and their VC round multiples. Start Free Trial | ||
nference Competitors
nference competitors include listed companies like IQVIA, GE HealthCare, ICON plc and Pro Medicus, and private ones like Innovaccer and NantHealth.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $16B | $3.4B | $44B | 3.4x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $8.3B | $816M | $13B | 1.9x | ||
| Publicly listed | $186M | $147M | $13B | 62.7x | ||
| Private | $250M | - | $3.5B | 13.8x | ||
| Private | $58M | - | $2B | - |
nference Public Comps
nference is still privately-owned, but its public comps include Natera, IQVIA, Agilent, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, Quest Diagnostics, Labcorp and Guardant Health.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.3B | ($266M) | 22.5x | 19.0x | (195.0x) | (261.5x) | |||
| $16B | $3.4B | 3.6x | 3.4x | 17.2x | 14.8x | |||
| $6.9B | $1.8B | 6.7x | 6.2x | 26.1x | 21.0x | |||
| $3.2B | $965M | 11.1x | 10.2x | 36.9x | 22.4x | |||
| $4.3B | $1.5B | 9.5x | 8.9x | 27.1x | 24.9x | |||
| $7.9B | $3.2B | 6.1x | 5.7x | 15.2x | 14.6x | |||
| $21B | $3.7B | 1.8x | 1.8x | 10.1x | 10.0x | |||
| $11B | $2.2B | 3.0x | 2.9x | 15.5x | 14.5x | |||
This data is available for Pro users. Sign up to see all nference competitors and their valuation data. Start Free Trial | ||||||||
Common questions about nference
| When was nference founded? | nference was founded in 2013. |
| Where is nference headquartered? | nference is headquartered in United States. |
| Is nference publicly listed? | No, nference is a private, VC-backed company. |
| How much funding has nference raised? | nference has raised $153M across 5 funding rounds. |
| What was nference's last funding round? | nference's last funding round was a $3M seed round in November 2022. |
| Who are nference's investors? | nference's investors include Matrix Capital Management, Matrix Partners, NTT Venture Capital, Mayo Clinic Ventures and A&E Investments. |
| Which companies are comparable to nference? | Companies comparable to nference include IQVIA, GE HealthCare, ICON plc, Pro Medicus, Innovaccer and NantHealth. |
| How many companies has nference acquired? | nference has acquired 1 company, including Predible Health. |
| How many companies has nference invested in? | nference has invested in 1 company, including Anumana. |
| What was nference's last investment? | In May 2021, nference invested in Anumana's $60M Series B alongside NTT Venture Capital, Mayo Clinic Ventures, Matrix Capital Management and 1 other investor. |
See companies similar to nference
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




